Trial Profile
Open, Single Arm,Multicenter Phase 2 Clinical Study to Evaluating the Efficacy and Safety of the Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) for CD19 Positive Lymphoma
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-CD19 CAR-transduced T cells (Primary)
- Indications B-cell lymphoma
- Focus Therapeutic Use
- Acronyms EECPL
- Sponsors Sinobioway Cell Therapy
- 06 Apr 2017 New trial record
- 21 Mar 2017 Planned Initiation date has been changed from 1 Mar 2017 to 1 Apr 2017.
- 21 Mar 2017 Status has been changed from recruiting to not yet recruiting